Divergent Roles for IRS-1 and IRS-2 in Breast Cancer Metastasis

The insulin receptor substrate (IRS) proteins are cytoplasmic docking proteins that function as essential signaling intermediates downstream of activated cell surface receptors, many of which have been implicated in breast cancer. The IRS proteins do not contain intrinsic kinase activity but rather function by organizing signaling complexes to initiate intracellular signaling cascades. IRS-1 and IRS-2 are expressed in normal mammary epithelial cells and in breast carcinoma cells, where they have been implicated in mediating signals to promote tumor cell survival, growth and motility. Although IRS-1 and IRS-2 are homologous, recent studies have revealed distinct functions for these adaptor proteins in regulating breast cancer progression. Specifically, IRS-2 is a positive regulator of metastasis, whereas IRS-1 may be a suppressor of metastasis. The observation that IRS-1 is inactivated in metastatic mammary tumors raises the possibility that IRS activity, rather than expression, may be a novel predictive indicator of metastasis. Understanding how the IRS proteins function in tumor progression is essential for future efforts aimed at developing approaches to target IRS-1 and IRS-2 in a diagnostic or therapeutic manner for the benefit of breast cancer patients.

[1]  C. Kahn,et al.  Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells , 1985, Nature.

[2]  R. Brand,et al.  Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.

[3]  C. Kahn,et al.  Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein , 1991, Nature.

[4]  M. White,et al.  IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. White,et al.  Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1 , 1993, Molecular and cellular biology.

[6]  Role of IRS-1-GRB-2 complexes in insulin signaling. , 1994, Molecular and cellular biology.

[7]  T. Yagi,et al.  Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 , 1994, Nature.

[8]  E. Ruoslahti,et al.  Association of insulin receptor substrate-1 with integrins. , 1994, Science.

[9]  C. Kahn,et al.  Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene , 1994, Nature.

[10]  M. White,et al.  The insulin receptor substrate-1-related 4PS substrate but not the interleukin-2R gamma chain is involved in interleukin-13-mediated signal transduction. , 1995, Blood.

[11]  William Arbuthnot Sir Lane,et al.  Role of IRS-2 in insulin and cytokine signalling , 1995, Nature.

[12]  J. Johnston,et al.  Interleukins 2, 4, 7, and 15 Stimulate Tyrosine Phosphorylation of Insulin Receptor Substrates 1 and 2 in T Cells POTENTIAL ROLE OF JAK KINASES (*) , 1995, The Journal of Biological Chemistry.

[13]  D. Accili,et al.  Tyrosine Phosphorylation of Insulin Receptor Substrate-1 in Vivo Depends upon the Presence of Its Pleckstrin Homology Region (*) , 1995, The Journal of Biological Chemistry.

[14]  M. White,et al.  Growth Hormone, Interferon-γ, and Leukemia Inhibitory Factor Promoted Tyrosyl Phosphorylation of Insulin Receptor Substrate-1 (*) , 1995, The Journal of Biological Chemistry.

[15]  G. Lienhard,et al.  Interleukin-9 Induces Tyrosine Phosphorylation of Insulin Receptor Substrate-1 via JAK Tyrosine Kinases (*) , 1995, The Journal of Biological Chemistry.

[16]  Lynne Yenush,et al.  The Pleckstrin Homology Domain Is the Principle Link between the Insulin Receptor and IRS-1* , 1996, The Journal of Biological Chemistry.

[17]  M. White,et al.  The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of Insulin Receptor Substrate 2 (*) , 1996, The Journal of Biological Chemistry.

[18]  E. Van Obberghen,et al.  Insulin Receptor Substrate-2 Binds to the Insulin Receptor through Its Phosphotyrosine-binding Domain and through a Newly Identified Domain Comprising Amino Acids 591786 (*) , 1996, The Journal of Biological Chemistry.

[19]  E. Van Obberghen,et al.  Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786. , 1996, The Journal of biological chemistry.

[20]  T. Ikeuchi,et al.  Insulin Receptor Substrate (IRS)-1 and IRS-2 Are Tyrosine-phosphorylated and Associated with Phosphatidylinositol 3-Kinase in Response to Brain-derived Neurotrophic Factor in Cultured Cerebral Cortical Neurons* , 1997, The Journal of Biological Chemistry.

[21]  S. Hilsenbeck,et al.  Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  I. Kerr,et al.  Janus Kinase-dependent Activation of Insulin Receptor Substrate 1 in Response to Interleukin-4, Oncostatin M, and the Interferons* , 1997, The Journal of Biological Chemistry.

[23]  G. Lienhard,et al.  A Novel 160-kDa Phosphotyrosine Protein in Insulin-treated Embryonic Kidney Cells Is a New Member of the Insulin Receptor Substrate Family* , 1997, The Journal of Biological Chemistry.

[24]  J. Backer,et al.  In vitro binding and phosphorylation of insulin receptor substrate 1 by the insulin receptor. Role of interactions mediated by the phosphotyrosine-binding domain and the pleckstrin-homology domain. , 1997, European journal of biochemistry.

[25]  M. White,et al.  Heterologous Pleckstrin Homology Domains Do Not Couple IRS-1 to the Insulin Receptor* , 1997, The Journal of Biological Chemistry.

[26]  E. Surmacz,et al.  Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. , 1997, Cancer research.

[27]  P. Glazer,et al.  Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. , 1997, Cancer research.

[28]  J. Flier,et al.  Divergent Signaling Capacities of the Long and Short Isoforms of the Leptin Receptor* , 1997, The Journal of Biological Chemistry.

[29]  G. Lienhard,et al.  The 60-kDa Phosphotyrosine Protein in Insulin-treated Adipocytes Is a New Member of the Insulin Receptor Substrate Family* , 1997, The Journal of Biological Chemistry.

[30]  M. Prisco,et al.  Differential roles of IRS‐1 and SHC signaling pathways in breast cancer cells , 1997, International journal of cancer.

[31]  N. Webster,et al.  Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. , 1998, Cancer research.

[32]  J. Kurebayashi,et al.  Dietary effects of fatty acids on growth and metastasis of KPL-1 human breast cancer cells in vivo and in vitro. , 1998, Anticancer research.

[33]  D. Yee,et al.  Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. , 1998, Cancer Research.

[34]  Sandra,et al.  A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. , 1998, Cancer research.

[35]  G. Stark,et al.  Growth Hormone and Prolactin Stimulate Tyrosine Phosphorylation of Insulin Receptor Substrate-1, -2, and -3, Their Association with p85 Phosphatidylinositol 3-Kinase (PI3-kinase), and Concomitantly PI3-kinase Activation via JAK2 Kinase* , 1998, The Journal of Biological Chemistry.

[36]  M. Korc,et al.  Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. , 1998, Cancer research.

[37]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[38]  D. Yee,et al.  Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.

[39]  S. Hilsenbeck,et al.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. , 1999, Molecular endocrinology.

[40]  M. White,et al.  Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signalling , 1999, Nature Genetics.

[41]  S. Andò,et al.  Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells , 1999, International journal of cancer.

[42]  L. Klein-Hitpass,et al.  Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. , 1999, Molecular endocrinology.

[43]  J. Pierce,et al.  Insulin receptor substrate-1 enhances growth hormone-induced proliferation. , 1999, Endocrinology.

[44]  W. Cavenee,et al.  IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation , 2000, Oncogene.

[45]  M. White,et al.  [Letters to nature] , 1975, Nature.

[46]  A. Benner,et al.  Down‐regulation of insulin‐like growth factor‐I receptor and insulin receptor substrate‐1 expression in advanced human breast cancer , 2000, International journal of cancer.

[47]  F. May,et al.  Insulin Receptor Substrate-1 Expression Is Regulated by Estrogen in the MCF-7 Human Breast Cancer Cell Line* , 2000, The Journal of Biological Chemistry.

[48]  G. Lienhard,et al.  Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis. , 2000, American journal of physiology. Endocrinology and metabolism.

[49]  Kristen L Murphy,et al.  Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis , 2000, Oncogene.

[50]  D. Wen,et al.  Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin* , 2001, The Journal of Biological Chemistry.

[51]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[52]  L. Kindblom,et al.  Growth hormone receptor is expressed in human breast cancer. , 2001, The American journal of pathology.

[53]  Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer , 2001, Breast Cancer Research.

[54]  L. Shaw.  Identification of Insulin Receptor Substrate 1 (IRS-1) and IRS-2 as Signaling Intermediates in the α6β4 Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase and Promotion of Invasion , 2001, Molecular and Cellular Biology.

[55]  D. Yee,et al.  Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines , 2001, Oncogene.

[56]  G. Lienhard,et al.  Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans , 2002, Diabetologia.

[57]  B. Kasinath,et al.  The type 2 vascular endothelial growth factor receptor recruits insulin receptor substrate-1 in its signalling pathway. , 2002, The Biochemical journal.

[58]  M. White,et al.  Phosphorylation of Ser307 in Insulin Receptor Substrate-1 Blocks Interactions with the Insulin Receptor and Inhibits Insulin Action* , 2002, The Journal of Biological Chemistry.

[59]  J. Kushner,et al.  Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation , 2003, The Journal of Neuroscience.

[60]  C. Clevenger.  Role of prolactin/prolactin receptor signaling in human breast cancer. , 2003, Breast disease.

[61]  Adrian V. Lee,et al.  Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2 , 2003, Oncogene.

[62]  John Calvin Reed,et al.  cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2 , 2003 .

[63]  C. Kahn,et al.  Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. , 2003, Endocrinology.

[64]  Xueying Lin,et al.  cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. , 2003, Genes & development.

[65]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[66]  L. Shaw,et al.  Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis , 2004, Molecular and Cellular Biology.

[67]  Johan Auwerx,et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.

[68]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[69]  E. Feldman,et al.  Insulin-like growth factor-I signaling in human neuroblastoma cells , 2004, Oncogene.

[70]  D. Yee,et al.  The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: Biology and therapeutic relevance , 2003, Cancer and Metastasis Reviews.

[71]  Chuong D. Hoang,et al.  Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells , 2004, Cancer Research.

[72]  Adrian V. Lee,et al.  A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells* , 2004, Journal of Biological Chemistry.

[73]  D. Yee,et al.  Motility Response to Insulin-like Growth Factor-I (IGF-I) in MCF-7 Cells is Associated with IRS-2 Activation and Integrin Expression , 2004, Breast Cancer Research and Treatment.

[74]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[75]  H. Kleinman,et al.  Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms , 2005, Oncogene.

[76]  M. Sułkowska,et al.  Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases , 2005, Journal of Clinical Pathology.

[77]  C. Desbois-Mouthon,et al.  Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. , 2005, The American journal of pathology.

[78]  Lewis C Cantley,et al.  Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. , 2005, Genes & development.

[79]  D. Yee,et al.  Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration , 2005, Breast Cancer Research and Treatment.

[80]  Adrian V. Lee,et al.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. , 2005, Cancer research.

[81]  H. Eldar-Finkelman,et al.  Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling* , 2005, Journal of Biological Chemistry.

[82]  Y. Le Marchand-Brustel,et al.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. , 2005, Biochimie.

[83]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[84]  Adrian V. Lee,et al.  Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. , 2006, Cancer research.

[85]  S. Andò,et al.  Expression of nuclear insulin receptor substrate 1 in breast cancer , 2006, Journal of Clinical Pathology.

[86]  M. White,et al.  The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling. , 2006, Molecular endocrinology.

[87]  B. Rueda,et al.  Leptin Signaling Promotes the Growth of Mammary Tumors and Increases the Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor Type Two (VEGF-R2)* , 2006, Journal of Biological Chemistry.

[88]  Leslie M. Shaw,et al.  Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis , 2006, Molecular and Cellular Biology.

[89]  S. Sukumar,et al.  Molecular links between obesity and breast cancer. , 2006, Endocrine-related cancer.

[90]  A. Carmichael,et al.  Obesity and prognosis of breast cancer , 2006, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[91]  M. White.  Regulating insulin signaling and beta-cell function through IRS proteins. , 2006, Canadian journal of physiology and pharmacology.

[92]  S. Byron,et al.  Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells , 2006, British Journal of Cancer.

[93]  M. White.  Regulating insulin signaling and β-cell function through IRS proteinsThis paper is one of a selection of papers published in this Special Issue, entitled Second Messengers and Phosphoproteins—12th International Conference. , 2006 .

[94]  Y. Chang,et al.  Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer. , 2006, Oncology reports.

[95]  Adrian V. Lee,et al.  Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2 , 2006, Molecular and Cellular Biology.